A detailed history of Tower Research Capital LLC (Trc) transactions in Nektar Therapeutics stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 17,881 shares of NKTR stock, worth $16,271. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,881
Previous 9,220 93.94%
Holding current value
$16,271
Previous $11,000 109.09%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.11 - $1.48 $9,613 - $12,818
8,661 Added 93.94%
17,881 $23,000
Q2 2024

Aug 13, 2024

BUY
$0.9 - $1.83 $8,298 - $16,872
9,220 New
9,220 $11,000
Q4 2023

Feb 13, 2024

SELL
$0.42 - $0.57 $5,172 - $7,019
-12,315 Reduced 54.49%
10,284 $5,000
Q3 2023

Nov 14, 2023

SELL
$0.51 - $1.05 $11,835 - $24,367
-23,207 Reduced 50.66%
22,599 $13,000
Q2 2023

Aug 14, 2023

BUY
$0.53 - $1.03 $2,521 - $4,900
4,758 Added 11.59%
45,806 $26,000
Q1 2023

May 09, 2023

BUY
$0.64 - $3.15 $19,367 - $95,322
30,261 Added 280.53%
41,048 $29,000
Q4 2022

Feb 10, 2023

SELL
$2.03 - $4.28 $7,675 - $16,182
-3,781 Reduced 25.95%
10,787 $24,000
Q3 2022

Nov 10, 2022

BUY
$3.04 - $5.14 $19,936 - $33,708
6,558 Added 81.87%
14,568 $47,000
Q2 2022

Aug 15, 2022

BUY
$3.17 - $6.17 $13,719 - $26,703
4,328 Added 117.54%
8,010 $31,000
Q1 2022

May 12, 2022

SELL
$4.16 - $13.72 $4,447 - $14,666
-1,069 Reduced 22.5%
3,682 $20,000
Q4 2021

Feb 14, 2022

SELL
$10.83 - $18.41 $74,640 - $126,881
-6,892 Reduced 59.19%
4,751 $64,000
Q3 2021

Nov 15, 2021

SELL
$13.07 - $18.84 $627 - $904
-48 Reduced 0.41%
11,643 $209,000
Q2 2021

Aug 16, 2021

BUY
$16.52 - $20.4 $31,388 - $38,760
1,900 Added 19.41%
11,691 $201,000
Q1 2021

May 17, 2021

SELL
$16.56 - $25.46 $92,421 - $142,092
-5,581 Reduced 36.31%
9,791 $196,000
Q4 2020

Feb 16, 2021

BUY
$15.77 - $19.03 $152,511 - $184,039
9,671 Added 169.64%
15,372 $261,000
Q3 2020

Nov 16, 2020

SELL
$16.59 - $24.79 $849,291 - $1.27 Million
-51,193 Reduced 89.98%
5,701 $95,000
Q2 2020

Aug 13, 2020

BUY
$16.86 - $23.44 $944,497 - $1.31 Million
56,020 Added 6409.61%
56,894 $1.32 Million
Q1 2020

May 15, 2020

SELL
$14.47 - $27.96 $120,535 - $232,906
-8,330 Reduced 90.5%
874 $16,000
Q4 2019

Feb 07, 2020

BUY
$15.87 - $23.12 $8,363 - $12,184
527 Added 6.07%
9,204 $199,000
Q3 2019

Nov 05, 2019

BUY
$16.91 - $36.27 $143,143 - $307,025
8,465 Added 3992.92%
8,677 $158,000
Q2 2019

Aug 13, 2019

SELL
$31.0 - $36.3 $257,176 - $301,144
-8,296 Reduced 97.51%
212 $8,000
Q1 2019

May 14, 2019

BUY
$31.58 - $46.35 $136,488 - $200,324
4,322 Added 103.25%
8,508 $285,000
Q4 2018

Feb 14, 2019

BUY
$30.43 - $56.65 $127,379 - $237,136
4,186 New
4,186 $138,000
Q3 2018

Nov 13, 2018

SELL
$46.46 - $68.49 $84,231 - $124,172
-1,813 Closed
0 $0
Q2 2018

Aug 15, 2018

BUY
$46.25 - $104.45 $83,851 - $189,367
1,813 New
1,813 $89,000
Q4 2017

Feb 09, 2018

SELL
$23.02 - $60.5 $389,475 - $1.02 Million
-16,919 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$17.79 - $24.0 $300,989 - $406,056
16,919
16,919 $406,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $171M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.